CD4(+) T-cell inhibitory ligands: a tool for characterizing dysfunctional CD4(+) T cells during chronic infection - PubMed
CD4(+) T-cell inhibitory ligands: a tool for characterizing dysfunctional CD4(+) T cells during chronic infection
Courtney Dow et al. Immunology. 2013 Sep.
Erratum in
- Immunology. 2013 Nov;140(3):390
Abstract
Activation of CD4(+) T cells helps to establish and maintain immune responses. During infection with lymphocytic choriomeningitis virus (LCMV) clone 13, the CD4(+) T-cell responses are lost. In this study, we were interested in the nature of the CD4(+) T-cell responses following infection with LCMV clone 13. To pursue this question, we infected C57BL/6 mice with LCMV clone 13. We used a GP66-80 MHC Class II tetramer to determine whether the CD4(+) T cells were present following infection with LCMV clone 13. We determined that the cells were present and antigen specific, but not functional. We attributed their dysfunction to the presence of CD4(+) T-cell inhibitory ligands. We further stained for the presence of CD4(+) T-cell inhibitory ligands. We found that the during chronic infection the number of CD4(+) T cells expressing programmed death-1 and CD160 were greater over the time-course study than the other CD4(+) T-cell inhibitory ligands. These data show that using CD4(+) T-cell inhibitory ligands as a reagent for characterization can help in understanding the complex immune responses associated with persistent infections.
Keywords: CD160; CD4+; lymphocytic choriomeningitis virus; programmed death-1; tetramer.
© 2013 The Authors. Immunology published by © 2013 John Wiley & Sons Ltd.
Figures

Quantification of antigen-specific CD4+ T cells over a 30-day infection period. C57BL/6 mice were infected intraperitoneally with 2 × 105 plaque-forming units (PFU) of lymphocytic choriomeningitis virus (LCMV) Armstrong, retro-orbitally with 2 × 106 PFU of LCMV clone 13, or left uninfected. Eight days post-infection, CD4+ T cells from splenocyte samples were stained and tested against phycoerythrin-conjugated MHC II tetramers. Samples were then sorted using flow cytometry and data were analysed using F
lowJ
o9.1. *P < 0·05.

Quantification of antigen-specific CD4+ GP66+ T cells was assessed over a 30-day time–course of infection. Splenocytes were collected and sorted using flow cytometry and data were analysed using F
lowJ
o9.1.

Quantification of CD4+ T-cell expression of programmed death 1 (PD-1) and CD160 over a 30-day infection period. C57BL/6 mice were infected intraperitoneally with 2 × 105 plaque-forming units (PFU) of lymphocytic choriomeningitis virus (LCMV) Armstrong, retro-orbitally with 2 × 106 PFU of LCMV clone 13, or left uninfected. Eight, 15 and 30 days post-infection, CD4+ T cells from splenocyte samples were stained with (a) αPD-1 (b) αCD160 murine antibodies. Samples were then sorted using flow cytometry and data were analysed using F
lowJ
o9.1. *P < 0·05.

Quantification of CD4+ T-cell expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3) expression over a 30-day infection period. C57BL/6 mice were infected intraperitoneally with 2 × 105 plaque-forming units (PFU) of lymphocytic choriomeningitis virus (LCMV) Armstrong, retro-orbitally with 2 × 106 PFU of LCMV clone 13, or left uninfected. Eight, 15 and 30 days post-infection, CD4+ T cells from splenocyte samples were stained with (a) αCTLA-4 (b) αLAG-3 murine antibodies. Samples were then sorted using flow cytometry and data were analysed using
FlowJo9.1.

Characterization of antigen-specific CD4+ T-cell expression of programmed death 1 (PD-1) over a 30-day infection period. C57BL/6 mice were infected intraperitoneally with 2 × 105 plaque-forming units (PFU) of lymphocytic choriomeningitis virus (LCMV) Armstrong, retro-orbitally with 2 × 106 PFU of LCMV clone 13, or left uninfected. Eight, 15 and 30 days post-infection, CD4+ T cells from splenocyte samples were stained with αPD-1 murine antibody. Samples were then sorted using flow cytometry and data were analysed using
FlowJo9.1. *P < 0·05.

Characterization of antigen-specific CD4+ T-cell expression of (a) CD160, (b) cytotoxic T-lymphocyte antigen 4 (CTLA-4) and (c) lymphocyte activation gene 3 (LAG-3) over a 30-day infection period. C57BL/6 mice were infected intraperitoneally with 2 × 105 plaque-forming units (PFU) of lymphocytic choriomeningitis virus (LCMV) Armstrong, retro-orbitally with 2 × 106 PFU of LCMV clone 13 or left uninfected. Eight, 15 and 30 days post-infection, CD4+ T cells from splenocyte samples were stained with αCD160, αCTLA-4 and αLAG-3 murine antibodies. Samples were then sorted using flow cytometry and data were analysed using
FlowJo9.1.

The concurrent expression of multiple inhibitory ligands [programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), CD160) on GP66+ CD4+ splenocytes from the three experimental groups at days 8, 15 and 30 post-infection. Individual populations were grouped based on total number of inhibitory ligands expressed using Boolean gating to analyse groups and SPICE for coexpression comparisons. The percentages of GP66+ CD4+ T-cells expressing combinations of inhibitory ligands are shown.
Similar articles
-
Mothé BR, Stewart BS, Oseroff C, Bui HH, Stogiera S, Garcia Z, Dow C, Rodriguez-Carreno MP, Kotturi M, Pasquetto V, Botten J, Crotty S, Janssen E, Buchmeier MJ, Sette A. Mothé BR, et al. J Immunol. 2007 Jul 15;179(2):1058-67. doi: 10.4049/jimmunol.179.2.1058. J Immunol. 2007. PMID: 17617598
-
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.
Matloubian M, Concepcion RJ, Ahmed R. Matloubian M, et al. J Virol. 1994 Dec;68(12):8056-63. doi: 10.1128/JVI.68.12.8056-8063.1994. J Virol. 1994. PMID: 7966595 Free PMC article.
-
Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H. Oxenius A, et al. Eur J Immunol. 1998 Jan;28(1):390-400. doi: 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O. Eur J Immunol. 1998. PMID: 9485218
-
Studstill CJ, Hahm B. Studstill CJ, et al. Viruses. 2021 Sep 29;13(10):1951. doi: 10.3390/v13101951. Viruses. 2021. PMID: 34696381 Free PMC article. Review.
-
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Anderson AC, Joller N, Kuchroo VK. Anderson AC, et al. Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001. Immunity. 2016. PMID: 27192565 Free PMC article. Review.
Cited by
-
Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M. Schnorfeil FM, et al. J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2. J Hematol Oncol. 2015. PMID: 26219463 Free PMC article.
-
Deciphering CD4+ T cell-mediated responses against cancer.
Kirkpatrick C, Lu YW. Kirkpatrick C, et al. Mol Carcinog. 2024 Jul;63(7):1209-1220. doi: 10.1002/mc.23730. Epub 2024 May 9. Mol Carcinog. 2024. PMID: 38725218 Review.
-
Liu X, Li F, Niu H, Ma L, Chen J, Zhang Y, Peng L, Gan C, Ma X, Zhu B. Liu X, et al. Front Immunol. 2019 Oct 2;10:2350. doi: 10.3389/fimmu.2019.02350. eCollection 2019. Front Immunol. 2019. PMID: 31632413 Free PMC article.
-
Cytotoxic CD4+ T cells in chronic viral infections and cancer.
Malyshkina A, Brüggemann A, Paschen A, Dittmer U. Malyshkina A, et al. Front Immunol. 2023 Oct 25;14:1271236. doi: 10.3389/fimmu.2023.1271236. eCollection 2023. Front Immunol. 2023. PMID: 37965314 Free PMC article. Review.
-
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Miggelbrink AM, Jackson JD, Lorrey SJ, Srinivasan ES, Waibl-Polania J, Wilkinson DS, Fecci PE. Miggelbrink AM, et al. Clin Cancer Res. 2021 Nov 1;27(21):5742-5752. doi: 10.1158/1078-0432.CCR-21-0206. Epub 2021 Jun 14. Clin Cancer Res. 2021. PMID: 34127507 Free PMC article. Review.
References
-
- Sant AJ, Chaves FA, Krafcik FR, Lazarski CA, Menges P, Richards K, Weaver JM. Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines. 2007;6:357–68. - PubMed
-
- Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials